1991
DOI: 10.1016/0002-8703(91)90002-y
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of restenosis by lovastatin after successful coronary angioplasty

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

1993
1993
2009
2009

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 153 publications
(14 citation statements)
references
References 29 publications
0
14
0
Order By: Relevance
“…These trials ranged in length from six months to seven years; there were 17 randomized trials [1][2][3][4]7,9,10,[12][13][14][15]17,18,[26][27][28]30 and 13 open-label studies. 8,11,14,16,[19][20][21][22][23][24][25]29,31 Tables 3 and 4 list the principal findings of the randomized clinical trials and open-label trials, respectively, and show estimates of the frequency of discontinuation of antihyperlipidemic therapy as compared with our findings in the two HMOs.…”
Section: Rates Of Drug Discontinuation In Long-term Clinical Trialsmentioning
confidence: 99%
See 1 more Smart Citation
“…These trials ranged in length from six months to seven years; there were 17 randomized trials [1][2][3][4]7,9,10,[12][13][14][15]17,18,[26][27][28]30 and 13 open-label studies. 8,11,14,16,[19][20][21][22][23][24][25]29,31 Tables 3 and 4 list the principal findings of the randomized clinical trials and open-label trials, respectively, and show estimates of the frequency of discontinuation of antihyperlipidemic therapy as compared with our findings in the two HMOs.…”
Section: Rates Of Drug Discontinuation In Long-term Clinical Trialsmentioning
confidence: 99%
“…‡Patients in this study were randomly assigned to receive two or more formulations of the same drug. 23 6 mo 37 29.7 (15.0-44.5) Olsson et al 25 6 mo 34 23.5 (9.3-37.8) Varthakavi et al 29 6 mo 36 22.2 (8.6-35.8) HMO 6 mo -26 (21)(22)(23)(24)(25)(26)(27)(28)(29)(30) …”
Section: Lovastatinmentioning
confidence: 99%
“…A recent meta-analysis showed that treatment with HMG-CoA reductase inhibitors (statins) decreased the risk of coronary heart disease by 31% and mortality by 21% [2]. Reduction of coronary heart disease with statins involves slowed progression of atherosclerosis, lesion regression [3]and inhibition of the development of new lesions, including the prevention of restenosis following balloon angioplasty [4]and stenting [5]. A major factor to which the success of statins in reducing coronary heart disease is attributed is the reduction of low-density lipoprotein (LDL) cholesterol [2].…”
Section: Introductionmentioning
confidence: 99%
“…This may be a result of less restenosis among the statin-treated patients. Since a small study in 1991 [26] suggested a potential beneficial effect of statin on restenosis, several additional studies [4,6] have reported similar findings in PCI patients. Moreover, a clinical trial of post-PCI patients [27] reported significantly slower plaque growth in the statin treatment arm compared with usual care.…”
Section: Discussionmentioning
confidence: 91%